Gannex, a wholly owned company of Ascletis Pharma Inc., fully dedicated to the R&D and commercialization of new drugs in the field of nonalcoholic steatohepatitis, announces the positive clinical results in overweight and obese subjects for ASC41, a liver-targeted prodrug.
February 21, 2021
· 3 min read